Apple is still trying to overturn the ban on the Apple Watch blood oxygen sensor

Apple is actively appealing a US International Trade Commission (ITC) ban on its Apple Watch blood oxygen sensor, with the US Court of Appeals for the Federal Circuit hearing new arguments in the ongoing patent dispute with health tech firm Masimo. Apple was compelled to remove the sensor in 2024 to resume sales of its Apple Watch Series 9 and Ultra 2 models, arguing that Masimo's own smartwatch development should not justify the ban. This legal battle is significant as Apple seeks to reintroduce the feature, which is central to its comprehensive health suite and potential future health functionalities.

Analysis

Apple (AAPL) is actively challenging a US International Trade Commission (ITC) ruling that led to the removal of the blood oxygen sensor from its Apple Watch Series 9 and Ultra 2 models sold in the US since early 2024. This action stems from a patent infringement finding in favor of health technology firm Masimo (MASI). The case, now before the US Court of Appeals, represents a significant strategic headwind for Apple, as the sensor is a key component of its increasingly important health and wellness ecosystem. The negative sentiment score of -0.7 for AAPL reflects this operational disruption and the potential long-term impairment of its competitive differentiation in the wearables market. Conversely, the sustained ban is a major validation of Masimo's intellectual property, underscored by its positive sentiment score of +0.7. The litigation is complex, with the article noting that Masimo itself was found to infringe on separate Apple patents, indicating a protracted and multifaceted legal battle over intellectual property in the lucrative health-tech space.

Key Decisions for Investors

• Investors in Apple should monitor the Federal Circuit appeal's outcome, as a continued ban could materially hamper the growth narrative and competitive positioning of its wearables division.
• For Masimo, the successful defense of its patents against Apple is a significant validation of its IP portfolio, but the high cost and protracted nature of this litigation remain a key risk factor to consider.
• The legal dispute presents an asymmetric risk/reward profile; while it is a notable headwind for a single product line at Apple, the outcome is fundamentally more critical to Masimo's valuation and market standing.
• The final court decision will likely serve as a significant catalyst for both stocks, creating potential short-term trading opportunities based on the binary outcome of the appeal.